Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis

Kyo Hwa Kang, Sang Yoon Park, Seung Bae Rho, Je Ho Lee

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)

Abstract

Aim: The tissue inhibitors of metalloproteinases (TIMPs) are complex molecules with both pro- and anti-tumour effects. Thus, their diverse expression could be because of their multifunctional properties with respect to tumour growth, angiogenesis, apoptosis, and other biological functions. Previous data have shown that TIMPs bind tightly to most matrix metalloproteinases, although the pathway that mediates angiostatic activity has not been fully established. Methods and results: As an initial step to elucidate the mechanism that regulates TIMP-3, we used a yeast two-hybrid system to screen a human ovary cDNA library for a novel TIMP-3-interacting partner. Here, we identified human angiotensin II type 2 receptor (AGTR2) as such a partner, which is well known to be a regulator of cardiovascular homoeostasis. In this present study, we investigated whether AGTR2-mediated apoptotic activity can inhibit the growth of ovarian cancer in an experimental model system. AGTR2 treatment was found to be more effective in inhibiting ovarian cancer growth than the treatment with TIMP-3 in parallel experiments. Subsequently, the efficacy of the combined treatment with TIMP-3 and AGTR2 was investigated. In the presence of both of these proteins, vascular endothelial growth factor-induced human umbilical vein endothelial cell proliferation was additively inhibited, and the inhibition of Akt and endothelial NO synthase phosphorylation was blocked. Conclusion: These combined results suggest that two angiostatic molecules may have an important biological role in regulating potent anti-angiogenic effects and possibly may have a role in anti-tumour therapy.

Original languageEnglish
Pages (from-to)150-160
Number of pages11
JournalCardiovascular Research
Volume79
Issue number1
DOIs
StatePublished - 1 Jul 2008

Fingerprint

Tissue Inhibitor of Metalloproteinase-3
Angiotensin Type 2 Receptor
Tissue Inhibitor of Metalloproteinases
Ovarian Neoplasms
Neoplasms
Growth
Two-Hybrid System Techniques
Human Umbilical Vein Endothelial Cells
Matrix Metalloproteinases
Gene Library
Nitric Oxide Synthase
Vascular Endothelial Growth Factor A
Ovary
Homeostasis
Theoretical Models
Phosphorylation
Cell Proliferation
Apoptosis
Proteins

Keywords

  • Angiogenesis
  • Angiotensin II type 2 receptor
  • Apoptosis
  • Therapeutic target
  • Tissue inhibitors of metalloproteinase

Cite this

@article{29194defab1c42c3a86cf6831e0e19c4,
title = "Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis",
abstract = "Aim: The tissue inhibitors of metalloproteinases (TIMPs) are complex molecules with both pro- and anti-tumour effects. Thus, their diverse expression could be because of their multifunctional properties with respect to tumour growth, angiogenesis, apoptosis, and other biological functions. Previous data have shown that TIMPs bind tightly to most matrix metalloproteinases, although the pathway that mediates angiostatic activity has not been fully established. Methods and results: As an initial step to elucidate the mechanism that regulates TIMP-3, we used a yeast two-hybrid system to screen a human ovary cDNA library for a novel TIMP-3-interacting partner. Here, we identified human angiotensin II type 2 receptor (AGTR2) as such a partner, which is well known to be a regulator of cardiovascular homoeostasis. In this present study, we investigated whether AGTR2-mediated apoptotic activity can inhibit the growth of ovarian cancer in an experimental model system. AGTR2 treatment was found to be more effective in inhibiting ovarian cancer growth than the treatment with TIMP-3 in parallel experiments. Subsequently, the efficacy of the combined treatment with TIMP-3 and AGTR2 was investigated. In the presence of both of these proteins, vascular endothelial growth factor-induced human umbilical vein endothelial cell proliferation was additively inhibited, and the inhibition of Akt and endothelial NO synthase phosphorylation was blocked. Conclusion: These combined results suggest that two angiostatic molecules may have an important biological role in regulating potent anti-angiogenic effects and possibly may have a role in anti-tumour therapy.",
keywords = "Angiogenesis, Angiotensin II type 2 receptor, Apoptosis, Therapeutic target, Tissue inhibitors of metalloproteinase",
author = "Kang, {Kyo Hwa} and Park, {Sang Yoon} and Rho, {Seung Bae} and Lee, {Je Ho}",
year = "2008",
month = "7",
day = "1",
doi = "10.1093/cvr/cvn072",
language = "English",
volume = "79",
pages = "150--160",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "1",

}

Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis. / Kang, Kyo Hwa; Park, Sang Yoon; Rho, Seung Bae; Lee, Je Ho.

In: Cardiovascular Research, Vol. 79, No. 1, 01.07.2008, p. 150-160.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis

AU - Kang, Kyo Hwa

AU - Park, Sang Yoon

AU - Rho, Seung Bae

AU - Lee, Je Ho

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Aim: The tissue inhibitors of metalloproteinases (TIMPs) are complex molecules with both pro- and anti-tumour effects. Thus, their diverse expression could be because of their multifunctional properties with respect to tumour growth, angiogenesis, apoptosis, and other biological functions. Previous data have shown that TIMPs bind tightly to most matrix metalloproteinases, although the pathway that mediates angiostatic activity has not been fully established. Methods and results: As an initial step to elucidate the mechanism that regulates TIMP-3, we used a yeast two-hybrid system to screen a human ovary cDNA library for a novel TIMP-3-interacting partner. Here, we identified human angiotensin II type 2 receptor (AGTR2) as such a partner, which is well known to be a regulator of cardiovascular homoeostasis. In this present study, we investigated whether AGTR2-mediated apoptotic activity can inhibit the growth of ovarian cancer in an experimental model system. AGTR2 treatment was found to be more effective in inhibiting ovarian cancer growth than the treatment with TIMP-3 in parallel experiments. Subsequently, the efficacy of the combined treatment with TIMP-3 and AGTR2 was investigated. In the presence of both of these proteins, vascular endothelial growth factor-induced human umbilical vein endothelial cell proliferation was additively inhibited, and the inhibition of Akt and endothelial NO synthase phosphorylation was blocked. Conclusion: These combined results suggest that two angiostatic molecules may have an important biological role in regulating potent anti-angiogenic effects and possibly may have a role in anti-tumour therapy.

AB - Aim: The tissue inhibitors of metalloproteinases (TIMPs) are complex molecules with both pro- and anti-tumour effects. Thus, their diverse expression could be because of their multifunctional properties with respect to tumour growth, angiogenesis, apoptosis, and other biological functions. Previous data have shown that TIMPs bind tightly to most matrix metalloproteinases, although the pathway that mediates angiostatic activity has not been fully established. Methods and results: As an initial step to elucidate the mechanism that regulates TIMP-3, we used a yeast two-hybrid system to screen a human ovary cDNA library for a novel TIMP-3-interacting partner. Here, we identified human angiotensin II type 2 receptor (AGTR2) as such a partner, which is well known to be a regulator of cardiovascular homoeostasis. In this present study, we investigated whether AGTR2-mediated apoptotic activity can inhibit the growth of ovarian cancer in an experimental model system. AGTR2 treatment was found to be more effective in inhibiting ovarian cancer growth than the treatment with TIMP-3 in parallel experiments. Subsequently, the efficacy of the combined treatment with TIMP-3 and AGTR2 was investigated. In the presence of both of these proteins, vascular endothelial growth factor-induced human umbilical vein endothelial cell proliferation was additively inhibited, and the inhibition of Akt and endothelial NO synthase phosphorylation was blocked. Conclusion: These combined results suggest that two angiostatic molecules may have an important biological role in regulating potent anti-angiogenic effects and possibly may have a role in anti-tumour therapy.

KW - Angiogenesis

KW - Angiotensin II type 2 receptor

KW - Apoptosis

KW - Therapeutic target

KW - Tissue inhibitors of metalloproteinase

UR - http://www.scopus.com/inward/record.url?scp=45849124160&partnerID=8YFLogxK

U2 - 10.1093/cvr/cvn072

DO - 10.1093/cvr/cvn072

M3 - Article

VL - 79

SP - 150

EP - 160

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 1

ER -